Retsevmo

Active substance Selpercatinib
Holder S.A. Eli Lilly N.V.
Status Closed
Indication  adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) following prior systemic therapy
Public documents Approbation
  Information for the patient
  Informed consent
Last update

11/08/2022

 

  

 

  

 

 

 

  

 

 

 

 

 

 
Last updated on 23/04/2024